ZURA Strangle Strategy
ZURA (Zura Bio Limited), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
ZURA (Zura Bio Limited) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $312.1M, a beta of 0.09 versus the broader market, a 52-week range of 0.98-7.44, average daily share volume of 623K, a public-listing history dating back to 2023, approximately 30 full-time employees. These structural characteristics shape how ZURA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.09 indicates ZURA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on ZURA?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ZURA snapshot
As of May 15, 2026, spot at $4.67, ATM IV 114.40%, IV rank 24.83%, expected move 32.80%. The strangle on ZURA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on ZURA specifically: ZURA IV at 114.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a ZURA strangle, with a market-implied 1-standard-deviation move of approximately 32.80% (roughly $1.53 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ZURA expiries trade a higher absolute premium for lower per-day decay. Position sizing on ZURA should anchor to the underlying notional of $4.67 per share and to the trader's directional view on ZURA stock.
ZURA strangle setup
The ZURA strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ZURA near $4.67, the first option leg uses a $4.90 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ZURA chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ZURA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $4.90 | N/A |
| Buy 1 | Put | $4.44 | N/A |
ZURA strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ZURA strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ZURA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on ZURA
Strangles on ZURA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ZURA chain.
ZURA thesis for this strangle
The market-implied 1-standard-deviation range for ZURA extends from approximately $3.14 on the downside to $6.20 on the upside. A ZURA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ZURA IV rank near 24.83% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ZURA at 114.40%. As a Healthcare name, ZURA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ZURA-specific events.
ZURA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ZURA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ZURA alongside the broader basket even when ZURA-specific fundamentals are unchanged. Always rebuild the position from current ZURA chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ZURA?
- A strangle on ZURA is the strangle strategy applied to ZURA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ZURA stock trading near $4.67, the strikes shown on this page are snapped to the nearest listed ZURA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ZURA strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ZURA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 114.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ZURA strangle?
- The breakeven for the ZURA strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ZURA market-implied 1-standard-deviation expected move is approximately 32.80%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ZURA?
- Strangles on ZURA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ZURA chain.
- How does current ZURA implied volatility affect this strangle?
- ZURA ATM IV is at 114.40% with IV rank near 24.83%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.